Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Merits and culprits of immunotherapies for neurological diseases in times of COVID-19.

EBioMedicine·2020
Same author

[Ocrelizumab for treatment of multiple sclerosis].

Der Nervenarzt·2020
Same author

Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS.

Neurology(R) neuroimmunology & neuroinflammation·2020
Same author

Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.

EBioMedicine·2020
Same author

COVID-19 and management of neuroimmunological disorders.

Nature reviews. Neurology·2020
Same author

Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.

Neurology·2020

Related Experiment Video

Updated: Apr 30, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K

Investigational approaches to multiple sclerosis therapy.

Joshua M Boeckers1, Marc Pawlitzki2, Hans-Peter Hartung2,3,4

  • 1Department of Neurology, Ruhr University Bochum, BG University Hospital Bergmannsheil, Bochum.

Current Opinion in Neurology
|April 29, 2026
PubMed
Summary
This summary is machine-generated.

New multiple sclerosis (MS) therapies aim to prevent disability and disease development. Emerging strategies include targeted immunomodulation, Epstein-Barr virus (EBV) treatments, remyelination agents, and cell-based therapies for MS progression.

Keywords:
Bruton's tyrosine kinase inhibitorsCD40L blockadeEpstein–Barr virus-targeted therapiesmultiple sclerosisremyelination strategies

More Related Videos

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

3.8K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

16.0K

Related Experiment Videos

Last Updated: Apr 30, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

3.8K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

16.0K

Area of Science:

  • Neuroimmunology
  • Therapeutic Development
  • Multiple Sclerosis Research

Background:

  • Multiple sclerosis (MS) research is shifting focus from relapse reduction to preventing disability progression and disease onset.
  • New therapeutic goals in MS include halting disease advancement and promoting central nervous system (CNS) repair.

Purpose of the Study:

  • To review emerging treatment strategies for multiple sclerosis (MS).
  • To summarize advancements in next-generation immunomodulation, Epstein-Barr virus (EBV) targeted therapies, remyelination agents, and cell-based treatments for MS.

Main Methods:

  • Review of current literature on emerging MS therapies.
  • Analysis of clinical trial data for novel immunomodulatory agents, EBV-directed strategies, remyelination candidates, and cell-based therapies.

Main Results:

  • Central nervous system (CNS) penetrant Bruton's tyrosine kinase (BTK) inhibitors show promise in slowing MS progression by targeting inflammation.
  • Fc-silent CD40L blockade demonstrates efficacy in suppressing magnetic resonance imaging (MRI) activity in MS.
  • Epstein-Barr virus (EBV)-directed strategies, including T-cell therapy and vaccines, are being explored to target a potential MS driver.
  • Remyelination agents show biological activity but limited clinical benefit; cell-based therapies are in early phases with initial biological signals.

Conclusions:

  • Advances in MS treatment signify a move towards precision immunomodulation and causal targeting.
  • Bruton's tyrosine kinase (BTK) inhibitors and CD40L blockade are promising candidates for addressing MS progression.
  • Future MS therapies will likely focus on CNS repair and targeting disease drivers like EBV.